Australia's largest stock trading and investment forum Australia's #1 stock forum

MSB

2.03%

$1.45 mesoblast limited

MSB trading, page-2428

First 2428 Last

Share
Profile

Follow
joeycav11

197 Posts.

142

04/11/18

13:12

Post #: 36383283
Share
Originally posted by LawyerTrader ↑

Agreed. Big Pharma has had every interest in trying to stymie Stem Cell based therapies. But it can't go on for much longer.

In 2017, the United States spent about $3.5 trillion, or 18 percent of GDP, on health expenditures – more than twice the average among developed countries. Of that $3.5 trillion, $1.5 trillion, is directly or indirectly financed by the federal government.

http://www.crfb.org/papers/american-health-care-health-spending-and-federal-budget

"The 21st Century Cures Act (Cures Act), signed into law on December 13, 2016, is designed to help accelerate medical product development and bring new innovations and advances to patients who need them faster and more efficiently.

The law builds on FDA's ongoing work to incorporate the perspectives of patients into the development of drugs, biological products, and devices in FDA's decision-making process. Cures enhances our ability to modernize clinical trial designs and clinical outcome assessments, which will speed the development and review of novel medical products, including medical countermeasures.

It also provides new authority to help FDA improve our ability to recruit and retain scientific, technical, and professional experts and it establishes new expedited product development programs, including:

The Regenerative Medicine Advanced Therapy, or RMAT, that offers a new expedited option for certain eligible biologics products."

https://www.fda.gov/regulatoryinfor...tstothefdcact/21stcenturycuresact/default.htm

And MSB is at the forefront of the Stem Cell revolution. What a time to be alive. What a time to be a shareholder.

Expand

Agreed great post Lawyertrader I think FDA is telling big pharma they better start making deals because approvoals are coming. And Meso is the undisputed leader in cell therapy
MSB Price at posting: $2.12 Sentiment: Buy Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

SWP

Swoop lobs $18M offer at microcap telecom Vonex – in which it holds 19.9%

MTH

Mithril's drilling in Mexico picks up silver at 997g/t, gold at 28g/t

NVU

Nanoveu surges 10% after benchmark testing for new AI chip begins

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

SNX

Sierra Nevada raises $2M for silver exploration at Blackhawk

M4M

Macro, Norden set up transport solutions initiative for West Pilbara

Week 42 Wrap: HotCopper's top picks; new ASX 200 record; world yawns at war

TLG

Talga Group wins key permit for flagship graphite mine in Sweden

IRX

InhaleRX snags $38.5M in funding from VC biotech funder Clendon

What's causing the cost-of-living crisis, and how to navigate it